Abstract
For the last several years, the drug industry primarily has relied on drugs that target a single gene or enzyme in a pathway involved in disease progression with the idea that such a drug will have minimum side effects and maximal efficacy. Recent observations, however, indicate that a drug that targets multiple genes/enzymes involved in several pathways, thus exhibiting promiscuity, is often more efficacious with less side effects. Thus significant efforts are being made to use our understanding in pharmacogenomics and structural biology to design polypharmacological drugs that are able to act at multiple sites. Recent studies with pathogenic bacteria demonstrate that such bacteria produce water-soluble, low molecular weight redox proteins that appear to act as weapons against various invaders, internal or external, of human body that cause diseases such as cancers, malaria or AIDS. The potential of finding such promiscuous lipophilic bacterial proteins active against multiple diseases may lead in the future to an antibiotic-like industry targeted towards non-prokaryotic agents of human diseases.
Keywords: Azurin, Cancer, Malaria, AIDS, Bacterial pathogenicity, Single and multiple target drugs
Letters in Drug Design & Discovery
Title: Designing Promiscuous Drugs? Look at What Nature Made!
Volume: 4 Issue: 1
Author(s): Arsenio M. Fialho, Tapas K. Das Gupta and Ananda M. Chakrabarty
Affiliation:
Keywords: Azurin, Cancer, Malaria, AIDS, Bacterial pathogenicity, Single and multiple target drugs
Abstract: For the last several years, the drug industry primarily has relied on drugs that target a single gene or enzyme in a pathway involved in disease progression with the idea that such a drug will have minimum side effects and maximal efficacy. Recent observations, however, indicate that a drug that targets multiple genes/enzymes involved in several pathways, thus exhibiting promiscuity, is often more efficacious with less side effects. Thus significant efforts are being made to use our understanding in pharmacogenomics and structural biology to design polypharmacological drugs that are able to act at multiple sites. Recent studies with pathogenic bacteria demonstrate that such bacteria produce water-soluble, low molecular weight redox proteins that appear to act as weapons against various invaders, internal or external, of human body that cause diseases such as cancers, malaria or AIDS. The potential of finding such promiscuous lipophilic bacterial proteins active against multiple diseases may lead in the future to an antibiotic-like industry targeted towards non-prokaryotic agents of human diseases.
Export Options
About this article
Cite this article as:
Fialho M. Arsenio, Das Gupta K. Tapas and Chakrabarty M. Ananda, Designing Promiscuous Drugs? Look at What Nature Made!, Letters in Drug Design & Discovery 2007; 4 (1) . https://dx.doi.org/10.2174/157018007778992946
DOI https://dx.doi.org/10.2174/157018007778992946 |
Print ISSN 1570-1808 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-628X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Manipulation of Dendritic Cells for Tumor Immunity
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Resistance to Anti-VEGF Agents
Current Pharmaceutical Design Nanotools for the Delivery of Antimicrobial Peptides
Current Drug Targets Nanotechnology and Antioxidant Therapy: An Emerging Approach for Neurodegenerative Diseases
Current Medicinal Chemistry CETUXIMAB: From Bench to Bedside
Current Cancer Drug Targets Current Management of Neonatal Liver Tumors
Current Pediatric Reviews A Review of Therapeutic Effects of Curcumin
Current Pharmaceutical Design Label-Free Cell Phenotypic Drug Discovery
Combinatorial Chemistry & High Throughput Screening Ovarian Cancer - Angiogenesis and Targeted Therapy
Current Angiogenesis (Discontinued) Can We Effectively Degrade Microcystins? - Implications on Human Health
Anti-Cancer Agents in Medicinal Chemistry The Stress Response: Implications for the Clinical Development of Hsp90 Inhibitors
Current Cancer Drug Targets Mitochondrial Generation of Reactive Oxygen Species and its Role in Aerobic Life
Current Medicinal Chemistry Potential Deployment of Angiotensin I Converting Enzyme Inhibitors and of Angiotensin II Type 1 and Type 2 Receptor Blockers in Cancer Chemotherapy
Anti-Cancer Agents in Medicinal Chemistry Current Concepts in Gastric Motility in Diabetes Mellitus
Current Diabetes Reviews Recent Developments in Targeting Bromodomain and Extra Terminal Domain Proteins for Cancer Therapeutics
Current Medicinal Chemistry Revising Skin Cancers by Means of Epigenetic Markers
Recent Patents on Biomarkers Clinical Pharmacology of EGFR/Met Inhibitors in Non-Small Cell Lung Cancer
Current Drug Targets Small Molecules for the Activation of Human γ δ T Cell Responses Against Infection
Recent Patents on Anti-Infective Drug Discovery The Role of Survivin for Radiation Oncology: Moving Beyond Apoptosis Inhibition
Current Medicinal Chemistry Does Hypoxic Response Mediate Primary Resistance to Sunitinib in Untreated Locally Advanced Breast Cancer?
Current Cancer Drug Targets